Pravin U. Dugel, M.D., is a distinguished ophthalmologist and a prominent figure in the field of retinal disease management. He currently serves as the Executive Chair, President, and Chief Executive Officer at Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. Dr. Dugel's leadership at Ocular Therapeutix has been instrumental in advancing the company's mission to bring novel treatments to patients suffering from various ophthalmic conditions. Before joining Ocular Therapeutix, Dr. Dugel had an illustrious career in ophthalmology, with a particular emphasis on retinal disorders. He founded Retinal Consultants of Arizona and served as its Managing Partner, where he was renowned for his clinical expertise and commitment to patient care. Dr. Dugel has authored over 200 peer-reviewed publications and has been an invited speaker at numerous national and international conferences. His contributions to the field have earned him several accolades, including the prestigious Senior Honor Award from the American Academy of Ophthalmology. In his role at Ocular Therapeutix, Dr. Dugel oversees the company's strategic direction and operational activities, guiding the development of its pipeline of innovative therapies. Under his leadership, the company has made significant progress in advancing its lead product candidates, including treatments for retinal vein occlusion and wet age-related macular degeneration. Dr. Dugel's vision and expertise continue to drive Ocular Therapeutix's growth and its commitment to improving the lives of patients with eye diseases.